News & Updates
Search Research Content
Resource Finder at Kennedy Krieger Institute
A free resource that provides access to information and support for individuals and families living with developmental disabilities.
Diphtheria toxin-based targeted toxin therapy for brain tumors.
|Title||Diphtheria toxin-based targeted toxin therapy for brain tumors.|
|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Li YM, Vallera DA, Hall WA|
|Journal||Journal of neuro-oncology|
|Date Published||2013 Sep|
Targeted toxins (TT) are molecules that bind cell surface antigens or receptors such as the transferrin or interleukin-13 receptor that are overexpressed in cancer. After internalization, the toxin component kills the cell. These recombinant proteins consist of an antibody or carrier ligand coupled to a modified plant or bacterial toxin such as diphtheria toxin (DT). These fusion proteins are very effective against brain cancer cells that are resistant to radiation therapy and chemotherapy. TT have shown an acceptable profile for toxicity and safety in animal studies and early clinical trials have demonstrated a therapeutic response. This review summarizes the characteristics of DT-based TT, the animal studies in malignant brain tumors and early clinical trial results. Obstacles to the successful treatment of brain tumors include poor penetration into tumor, the immune response to DT and cancer heterogeneity.
|Alternate Journal||J. Neurooncol.|